Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple ultrasound score predict dangerous placental complications?

NCT ID NCT07755709

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether a new ultrasound scoring system can accurately predict the severity of placenta accreta spectrum (PAS), a condition where the placenta grows too deeply into the uterine wall. The study will enroll 50 pregnant women with placenta previa and a history of uterine surgery, and compare ultrasound scores with actual findings during cesarean delivery. The goal is to see if the score can predict the need for hysterectomy, bladder injury, blood transfusions, and ICU admission, potentially improving surgical planning and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A novel ultrasound scoring system
What this could lead to
If successful, this scoring system could help doctors predict the severity of placenta accreta before delivery, potentially reducing complications by guiding surgical planning.
What could go wrong
This is a small, early-stage study, and the scoring system may not prove accurate enough for widespread use. It is also limited to a specific group of pregnant women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women aged 18 to 45 years. Gestational age ≥28 weeks at the time of enrollment. Diagnosed Placenta Previa with a history of: One or more previous cesarean sections Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women aged 18 to 45 years. * Gestational age ≥28 weeks at the time of enrollment. * Diagnosed Placenta Previa with a history of: * One or more previous cesarean sections * Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty). * Singleton pregnancy. Exclusion Criteria: * Women with multiple pregnancies (twins, triplets, etc.). * Pregnancies complicated by acute medical conditions (e.g., heart failure, uncontrolled diabetes). * Prior history of Blood diseases. (other than those related to pregnancy). * Women who refuse to participate or withdraw consent during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Placenta accreta, third trimester are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.